Mounting evidence suggests Sputnik COVID vaccine is safe and effective.

@article{Nogrady2021MountingES,
  title={Mounting evidence suggests Sputnik COVID vaccine is safe and effective.},
  author={Bianca Nogrady},
  journal={Nature},
  year={2021}
}
Controversy surrounding the Sputnik V vaccine
TLDR
It is imperative to document the efficacy and safety of the Sputnik V vaccine in individuals with high pre-existing anti-Ad26 and Ad5-neutralizing antibody titres and in those under the age of 18 or older than 60 years and be certain that Sputnick V does not cause the rare development of immune thrombotic thromBocytopenia. Expand
COVID-19 Vaccines: Current Conditions and Future Prospects
TLDR
An overview of the current SARS-CoV-2 vaccines with their mechanisms of action, current technologies utilized in manufacturing of the vaccines, and limitations in this new field with emerging data is provided. Expand
The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia’s Vaccine Rollout Slower than That of Other Nations?
The emergence of the SARS-CoV-2 pandemic in the beginning of 2020 led to the deployment of enormous amounts of resources by different countries for vaccine development, and the Russian Federation wasExpand
The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis
  • Danielle Soares de Oliveira Daian e Silva, Flávio Guimarães da Fonseca
  • Medicine
  • Vaccines
  • 2021
The COVID-19 pandemic represents a milestone in vaccine research and development in a global context. A worldwide effort, as never seen before, involved scientists from all over the world in favor ofExpand

References

SHOWING 1-4 OF 4 REFERENCES
ACTIVE SURVEILLANCE OF THE SPUTNIK V VACCINE IN HEALTH WORKERS
TLDR
This study shows high rates of local and systemic reactions however early serious events were rare, and active surveillance on safety for vaccines with emergency approval is mandatory. Expand
ROCCA study protocol and interim analysis on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino: an observational study using active surveillance
TLDR
The ROCCA interim analysis confirmed a good tolerability profile in the over 60 years age group after both doses regarding short-term solicited AEFI to Sputnik V (Gam-COVID-Vac). Expand
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
TLDR
This interim analysis of the phase 3 trial of Gam-COVID-Vac showed 91·6% efficacy against COVID-19 and was well tolerated in a large cohort. Expand
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
TLDR
The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants and was safe and well tolerated. Expand